Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial

Journal of Hepatology

Volumn 63, Issue 6, 2015, Pages 1476-1483

  Scorletti, Eleonora ^a,b   West, Annette L ^a   Bhatia, Lokpal ^a,b   Hoile, Samuel P ^a   McCormick, Keith G ^a,b   Burdge, Graham C ^a   Lillycrop, Karen A ^a   Clough, Geraldine F ^a   Calder, Philip C ^a,b   Byrne, Christopher D ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b University Hospital Southampton NHS Foundation Trust   (United Kingdom)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Liver fat; NAFLD; Omega 3 fatty acid; PNPLA3; Triglyceride; WELCOME, Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOCOSAHEXAENOIC ACID; EZETIMIBE; FAT; FIBRIC ACID DERIVATIVE; GLUTAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LEVOTHYROXINE; LYSINE; MEMBRANE PROTEIN; OMEGA 3 ACID ETHYL ESTER; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 3; PLACEBO; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TRANSMEMBRANE 6 SUPERFAMILY MEMBER 2 PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; DRUG COMBINATION; TM6SF2 PROTEIN, HUMAN; TRIACYLGLYCEROL LIPASE;

ADULT; AMINO ACID SUBSTITUTION; ANALYSIS OF COVARIANCE; ARTICLE; BLOOD SAMPLING; CONFOUNDING VARIABLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; ERYTHROCYTE; FEMALE; GAS CHROMATOGRAPHY; GENOTYPE; HUMAN; LINEAR REGRESSION ANALYSIS; LIPID BLOOD LEVEL; LIVER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; DIET THERAPY; DIETARY SUPPLEMENT; DRUG COMBINATION; DRUG EFFECTS; GENETIC VARIATION; GENETICS; LIPID METABOLISM; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; LIPASE; LIPID METABOLISM; LIVER; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 84951567812     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.07.036     Document Type: Article

References (42)

1. G. Targher, and C.D. Byrne Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications J Clin Endocrinol Metab 98 2013 483 495
2. G. Marchesini, and A. Mazzotti NAFLD incidence and remission: only a matter of weight gain and weight loss? J Hepatol 62 2015 15 17
3. D.C. Chan, G.F. Watts, T.A. Mori, P.H. Barrett, T.G. Redgrave, and L.J. Beilin Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity Am J Clin Nutr 77 2003 300 307
4. F. Nascimbeni, R. Pais, S. Bellentani, C.P. Day, V. Ratziu, P. Loria, and et al. From NAFLD in clinical practice to answers from guidelines J Hepatol 59 2013 859 871
5. -WELCOME study Hepatology 60 2014 1211 1221
6. C.K. Argo, J.T. Patrie, C. Lackner, T.D. Henry, E.E. de Lange, A.L. Weltman, and et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial J Hepatol 62 2015 190 197
7. V. Nobili, G. Bedogni, A. Alisi, A. Pietrobattista, P. Rise, C. Galli, and et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial Arch Dis Child 96 2011 350 353
8. H.M. Parker, N.A. Johnson, C.A. Burdon, J.S. Cohn, H.T. O'Connor, and J. George Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis J Hepatol 56 2012 944 951
9. A.J. Sanyal, M.F. Abdelmalek, A. Suzuki, O.W. Cummings, and M. Chojkier No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial Gastroenterology 147 2014 377 384
10. T.A. Mori, and R.J. Woodman The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans Curr Opin Clin Nutr Metab Care 9 2006 95 104
11. T.A. Mori, V. Burke, I.B. Puddey, G.F. Watts, D.N. O'Neal, J.D. Best, and et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men Am J Clin Nutr 71 2000 1085 1094
12. R.J. Woodman, T.A. Mori, V. Burke, I.B. Puddey, A. Barden, G.F. Watts, and et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients Atherosclerosis 166 2003 85 93
13. M.D. Mesa, R. Buckley, A.M. Minihane, and P. Yaqoob Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein Atherosclerosis 175 2004 333 343
14. E.C. Leigh-Firbank, A.M. Minihane, D.S. Leake, J.W. Wright, M.C. Murphy, B.A. Griffin, and et al. Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses Br J Nutr 87 2002 435 445
15. S. Romeo, J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, L.A. Pennacchio, and et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat Genet 40 2008 1461 1465
16. D.G. Mashek, and A.S. Greenberg Serum TAG analysis differentiates between genetic and obesity-associated NAFLD Diabetes 63 2014 42 44
17. J. Hyysalo, P. Gopalacharyulu, H. Bian, T. Hyotylainen, M. Leivonen, N. Jaser, and et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity Diabetes 63 2014 312 322
18. G.C. Farrell PNPLeAse get the fats right: does lipogenesis or lipolysis cause NASH? Hepatology 52 2010 818 821
19. C. Pirazzi, M. Adiels, M.A. Burza, R.M. Mancina, M. Levin, M. Stahlman, and et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro J Hepatol 57 2012 1276 1282
20. H. Ruhanen, J. Perttila, M. Holtta-Vuori, Y. Zhou, H. Yki-Jarvinen, E. Ikonen, and et al. PNPLA3 mediates hepatocyte triacylglycerol remodeling J Lipid Res 55 2014 739 746
21. P. Pingitore, C. Pirazzi, R.M. Mancina, B.M. Motta, C. Indiveri, A. Pujia, and et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function Biochim Biophys Acta 1841 2014 574 580
22. R.M. Mancina, N. Matikainen, C. Maglio, S. Soderlund, N. Lundbom, A. Hakkarainen, and et al. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant J Clin Endocrinol Metab 100 2015 E821 E825
23. A. Peter, M. Kovarova, S. Nadalin, T. Cermak, A. Konigsrainer, F. Machicao, and et al. PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans Diabetologia 57 2014 2103 2107
24. B. Kahali, Y.L. Liu, A.K. Daly, C.P. Day, Q.M. Anstee, and E.K. Speliotes TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology 148 2015 679 684
25. P. Dongiovanni, S. Petta, C. Maglio, A.L. Fracanzani, R. Pipitone, E. Mozzi, and et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease Hepatology 61 2015 506 514
26. E. Scorletti, L. Bhatia, K.G. McCormick, G.F. Clough, K. Nash, P.C. Calder, and et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease Contemp Clin Trials 37 2014 301 311
27. K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, and et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
28. K. Cusi, Z. Chang, S. Harrison, R. Lomonaco, F. Bril, B. Orsak, and et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease J Hepatol 60 2014 167 174
29. S. Robinson, H. Syddall, K. Jameson, S. Batelaan, H. Martin, E.M. Dennison, and et al. Current patterns of diet in community-dwelling older men and women: results from the Hertfordshire Cohort Study Age Ageing 38 2009 594 599
30. L.M. Browning, C.G. Walker, A.P. Mander, A.L. West, J. Madden, J.M. Gambell, and et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish Am J Clin Nutr 96 2012 748 758
31. G.C. Burdge, P. Wright, A.E. Jones, and S.A. Wootton A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction Br J Nutr 84 2000 781 787
32. J. Folch, M. Lees, and G.H. Sloane Stanley A simple method for the isolation and purification of total lipides from animal tissues J Biol Chem 226 1957 497 509
33. S. Sookoian, and C.J. Pirola Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease Hepatology 53 2011 1883 1894
34. P. Dongiovanni, B. Donati, R. Fares, R. Lombardi, R.M. Mancina, S. Romeo, and et al. PNPLA3 I148M polymorphism and progressive liver disease World J Gastroenterol 19 2013 6969 6978
35. J. Shen, G.L. Wong, H.L. Chan, R.S. Chan, H.Y. Chan, W.C. Chu, and et al. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease J Gastroenterol Hepatol 30 2015 139 146
36. W. Stillwell, and S.R. Wassall Docosahexaenoic acid: membrane properties of a unique fatty acid Chem Phys Lipids 126 2003 1 27
37. Z.S. Tan, W.S. Harris, A.S. Beiser, R. Au, J.J. Himali, S. Debette, and et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging Neurology 78 2012 658 664
38. N. Santoro, M. Savoye, G. Kim, K. Marotto, M.M. Shaw, B. Pierpont, and et al. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake PLoS One 7 2012 e37827
39. C. Wojcik, K. Lohe, C. Kuang, Y. Xiao, Z. Jouni, and E. Poels Modulation of adipocyte differentiation by omega-3 polyunsaturated fatty acids involves the ubiquitin-proteasome system J Cell Mol Med 18 2014 590 599
40. V. Nobili, G. Bedogni, B. Donati, A. Alisi, and L. Valenti The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease J Med Food 16 2013 957 960
41. P. Dongiovanni, S. Petta, V. Mannisto, M.R. Margherita, R. Pipitone, V. Karja, and et al. Statin use and nonalcoholic steatohepatitis in at risk individuals J Hepatol 63 2015 705 712
42. C.N. Palmer, C. Maglio, C. Pirazzi, M.A. Burza, M. Adiels, L. Burch, and et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant PLoS One 7 2012 e39362